Quinidine-Induced Microvolt Electrocardiographic Alternans.

Area of Science:

• Cardiology
• Pharmacology
• Biomedical Engineering

Background:

• Quinidine, a Class Ia antiarrhythmic, is linked to increased ventricular arrhythmia and sudden death risk.
• Electrocardiographic alternans (ECGA) are recognized indicators of arrhythmia risk.
• Previous ECGA detection focused on T-wave alternans (TWA).

Purpose of the Study:

• To confirm and track quinidine's proarrhythmic risk using ECGA.
• To evaluate ECGA changes in healthy subjects before and after quinidine administration.
• To assess the Enhanced Correlation Method (ECM) for detecting various ECGA forms.

Main Methods:

• Utilized the "ECG Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects" database.
• Employed the Enhanced Correlation Method (ECM) to quantify P-wave alternans (PWA), QRS-complex alternans (QRSA), and T-wave alternans (TWA).
• Analyzed ECGs from healthy subjects pre- and post-quinidine administration (within 24 hours).

Main Results:

• Quinidine administration significantly increased ECGA within 6 hours, correlating with its elimination half-life.
• Maximum ECGA increase ranged from two to four times baseline values.
• ECGA magnitude detected transient changes more effectively than amplitude, with significant differences noted 3.5-7 hours post-dose.

Conclusions:

• ECGA, detected by ECM, effectively reveals the proarrhythmic risk associated with quinidine.
• The study validates ECGA as a sensitive marker for drug-induced arrhythmia risk.
• Findings contribute to safer quinidine therapy guidance through ECGA monitoring.